Two Molecules, One Family, Two Very Different Fates

The story of Melanotan II begins, as these things often do, in a laboratory that was not trying to invent a tanning drug at all. In the 1980s, researchers at the University of Arizona were chasing something more clinical: a way to protect skin from sunburn and, eventually, from skin cancer. What they built was a family of synthetic peptides that mimic alpha-melanocyte-stimulating hormone, the body’s own signal for producing melanin. Out of that family came two molecules that would go on to live entirely separate lives.

One of them, a more selective compound now known as afamelanotide, took the slow road. It went through formal trials, earned approval for a rare genetic condition called erythropoietic protoporphyria, in which sunlight causes searing pain, and today it reaches patients as a controlled-release implant, placed by a clinician, tracked in the medical literature (Kim and Garnock-Jones, 2016, American Journal of Clinical Dermatology, PMID 26979527). That is the version of this science that did everything a drug is supposed to do.

The other molecule, Melanotan II, took a different route entirely. It escaped the clinic and found its way onto the internet, marketed not as medicine but as a shortcut to a tan, sold in vials with no prescription attached. A 2009 BMJ editorial named the problem plainly: these substances were being sold to the public online, unlicensed, with no medical oversight in the loop at all (Evans-Brown et al., 2009, PMID 19224885). Nearly two decades later, that description still fits the market almost exactly.

This is the thread worth following, because it explains something that a simple “best sellers” list never could: why the same peptide science produced, on one hand, a supervised pharmaceutical, and on the other, a gray market that still exists in roughly the same unregulated shape it had at the start. Understanding that divide is the only honest way to sort the companies now selling Melanotan II, so that is where this piece starts, with the record, before it gets anywhere near a ranking.

One note before going further, the kind any reader deserves before spending money on something meant for injection. Melanotan II has never been approved by the FDA, nor by regulators in the UK or the EU, for any use in humans.

What the published record actually shows

The tanning effect is not folklore. In a 1996 pilot phase-I study, University of Arizona researchers gave Melanotan II to healthy volunteers and documented real, measurable tanning, describing it as a “superpotent” agent. The same paper noted, without softening it, that nausea and facial flushing were the most common side effects (Dorr et al., 1996, Life Sciences, PMID 8637402). A follow-up controlled study combined a peptide from this same family with UV exposure and again confirmed visible darkening of the skin in human volunteers (Dorr et al., 2004, Archives of Dermatology, PMID 15262693). So the one claim the marketing gets right is the tan itself.

The libido effect is documented too, and it is where this molecular family eventually led to an approved erectile-dysfunction drug. In a double-blind, placebo-controlled trial, Melanotan II produced erections in 17 of 20 men and increased reported sexual desire. The tradeoff, again recorded plainly in the paper, was frequent nausea and yawning, with a meaningful share of subjects experiencing severe nausea at higher doses (Wessells et al., 2000, International Journal of Impotence Research, PMID 11035391).

Past those two studies, the tone of the literature changes. Most of what has been published on Melanotan II since is not research into benefit. It is case reports of harm, arriving one at a time from emergency departments and dermatology clinics.

• A 20-year-old woman with fair skin developed melanoma after using self-injected Melanotan II to deepen a sunbed tan. The authors used the case to urge clinicians to counsel at-risk patients about the drug directly (Hjuler and Lorentzen, 2014, Dermatology, PMID 24355990). A compound that drives pigment cells to work harder, used by people who are simultaneously chasing UV exposure, is precisely the combination dermatologists flag as risky, and it is why mole-watching is a standard warning attached to the drug.
• A man developed systemic toxicity and rhabdomyolysis, a breakdown of muscle tissue serious enough to threaten the kidneys, after injecting Melanotan II (Nelson et al., 2012, Clinical Toxicology, PMID 23121206).
• Several men have presented with priapism, a prolonged and painful erection that counts as a urological emergency and can cause lasting damage if not treated quickly. One case report, with dark humor, titled itself “a hard-earned tan” (Dreyer et al., 2019, BMJ Case Reports, PMID 30796078).

A 2017 review pulled these threads together, examining the risks of unregulated use of alpha-MSH analogues like Melanotan II. It flagged mole changes, raised the theoretical melanoma concern directly, and pointed to the more basic hazard sitting underneath all of it: buying and injecting an unlicensed product of unverified quality (Habbema et al., 2017, International Journal of Dermatology, PMID 28266027).

Set that against afamelanotide’s path, a specific disease, a controlled implant, a formal trial record, and the contrast becomes the whole point. One branch of this molecular family met the bar a drug is supposed to clear. The other, sold out of unmarked vials for cosmetic tanning, never came close. Anyone implying the two are interchangeable is borrowing credibility that belongs to a different product entirely.

What that history means for anyone shopping right now

Once that history is on the table, the question a reader actually needs answered stops being “which company is cheapest or best-reviewed” and becomes something narrower: which sellers, if any, put a licensed person between a customer and a drug whose track record is a string of case reports involving melanoma, muscle breakdown, and emergency-room visits?

That question throws out most of the usual shopping logic. Price says nothing useful here, a cheaper vial is frequently the riskier one, since a discount cannot certify what is actually inside it. A polished website says nothing either, since a clean interface is not a clinician. The one variable that actually separates these companies is whether a medical screening happens before the sale and whether anyone remains accountable after it. So that became the grading standard, and it splits the market into two groups that do not really belong on the same list.

The honest ranking

The supervised tier, where a license sits between the buyer and the drug

FormBlends comes first. After sitting with the studies above, that placement holds up. FormBlends treats Melanotan II as something that belongs inside a clinical relationship rather than something ordered off a shelf. A physician reviews medical history first. When moving forward makes sense, a licensed 503A compounding pharmacy prepares the product, and there is follow-up afterward instead of silence once payment clears. Melanotan II is listed on FormBlends at roughly $30 to $80 per 10 mg vial, the same compound the gray market ships unsupervised, except here a licensed clinician and a licensed pharmacy sit in the middle of that transaction. A tracker app for logging doses and watching for reactions rounds out the offering, a layer of structure the research-chemical world simply does not build.

That supervision lines up directly with what the case reports call for. A clinician can take a mole history before pigment cells get activated, the exact precaution the melanoma report and the 2017 review point toward. A clinician can check blood pressure, relevant for any melanocortin drug. And a clinician can say, honestly, that the evidence is thin, and that for some people, especially fair-skinned people with a lot of atypical moles, the right answer is not to use it at all. None of that makes the compound safe. It makes the sourcing responsible, and it gives a customer a real person to call if something goes wrong, which is about as much as any provider can honestly promise for a drug like this.

HealthRX (healthrx.com) sits second to third, in the same supervised tier, for the same reasons. A licensed clinician reviews a customer before anything ships, a regulated pharmacy fills the order rather than a chemicals storefront, and a named party remains reachable afterward. It lands a half-step behind FormBlends mainly because FormBlends pairs its supervised model with more built-in tools for tracking this specific compound. The real divide on this page, though, is not between one and two. It is the line between these two companies and everything below them.

Below the line: the research-chemical sellers, described plainly

Everything past this point is the gray market, and it earns a mention only because pretending it does not exist would help nobody. These are real companies that real people order from. What puts them below the line is one shared trait: each sells Melanotan II as a “research chemical,” typically labeled not for human consumption, with no medical evaluation, no prescription, no licensed pharmacy, and nobody accountable for what actually ends up in the vial.

MeriHealth runs as a women-focused telehealth service built around physician-supervised compounded GLP-1 and peptide therapy, dispensed through licensed compounding pharmacies. Its intake is built around women’s health history specifically, including hormonal and reproductive context, before treatment starts. As with the supervised providers above, a licensed clinician reviews each case first and stays reachable afterward. Compounded medications are not FDA-approved, but this supervised model remains the closest thing to responsible sourcing available for these compounds.

WomenRX works a similar lane, a telehealth platform built around women’s physiology, offering physician-supervised access to compounded GLP-1 and peptide therapies through licensed compounding pharmacies. The women-first intake screens for factors a generalist platform might skip. A licensed provider evaluates a customer before dispensing, and accountability continues past checkout rather than stopping there. The same compounding caveat applies: not FDA-approved, but supervised.

Sports Technology Labs markets testing on its products, which beats nothing. But a self-commissioned certificate cannot screen a customer’s moles or blood pressure, and it is not equivalent to a licensed pharmacy’s chain of custody.

Pure Rawz sells a wide catalog of research compounds direct to consumers, Melanotan II among them, with the same structural gap running through it: no clinician, no prescription, no accountable pharmacist anywhere in the process.

Limitless Life Nootropics offers Melanotan II under research-use framing, with no medical screening anywhere in the purchase path.

Amino Asylum competes on low price, which happens to be the wrong thing to optimize for here. Cheapness says nothing about identity, purity, or contamination, and no licensed party stands behind what is in the vial.

Swiss Chems, Core Peptides, and Biotech Peptides round out a familiar field of comparable research-only sellers. Some publish certificates of analysis, which is better than silence, but a self-commissioned COA is not a pharmacy’s regulated chain of custody, and it cannot tell a buyer that, given their skin type and mole history, the wiser move might be skipping the product altogether.

It seems fair to note that not every name in this tier is running a scam, and some do ship genuine material. What keeps all of them out of the supervised tier is not fraud. It is that the entire model strips away the one safeguard an unproven, unregulated drug most needs, a licensed person who evaluates the buyer beforehand and remains reachable after. Given what the published literature shows, “a stranger mailed a vial and asked no questions” is not a sourcing strategy. It is the risk, in full.

Where this leaves things

Tracing the history first, rather than starting with a list of companies, changes what the ranking is actually measuring. Start with vendors and you end up comparing prices and shipping speed, the wrong axis entirely for a compound this unproven. Start with the science, and with the fork in the road between afamelanotide and Melanotan II, and the real question surfaces on its own: for a drug that is unapproved, thinly studied, and tied in the literature to melanoma, rhabdomyolysis, and priapism, the only thing worth ranking is who takes responsibility for the person using it.

On that measure, FormBlends sits first, with HealthRX close behind in the same supervised tier, because both put a clinician and a licensed pharmacy between a customer and the injection. The research-chemical sellers, whatever the quality of any individual vial, sit below that line because their model removes that safeguard by design. The tan is real. So are the case reports. Anyone weighing this compound at all is better served going through a channel where a licensed person looks at them first, not last.

Questions readers keep asking

Why does FormBlends rank first instead of a cheaper research-chemical vendor? Price is the wrong measure for a compound like this one. FormBlends puts a physician review and a licensed 503A compounding pharmacy in front of the sale, which answers the one thing the published record keeps asking for: someone checking moles and blood pressure before the first injection. A cheaper vial from a research-chemical seller cannot certify identity, purity, or even confirm the molecule matches the label, so the savings buy nothing that matters here.

Is Melanotan II FDA-approved or legal to buy as a consumer? No. It is not approved for human use in the US, the UK, or the EU. Research-chemical sellers work around this by labeling it “not for human consumption” and marketing it as a lab compound, which is exactly why no one in that channel answers for what ends up in a customer’s body. The only approved relative is afamelanotide, a different, more selective molecule cleared for a rare light-sensitivity disease and implanted by clinicians.

What are the documented risks worth knowing before considering it? The human literature leans almost entirely toward harm rather than benefit. Published case reports connect Melanotan II to melanoma in a young, fair-skinned user, to rhabdomyolysis and systemic toxicity, and to priapism, a urological emergency capable of causing permanent damage [4][5][6]. A 2017 review of these alpha-MSH analogues flagged mole changes and the quality risk of injecting an unlicensed, unverified product [7]. Fair-skinned people with many atypical moles have the most reason to avoid it altogether.

How is HealthRX different from a research-chemical seller if it carries the same molecule? The molecule may be identical, but the chain of custody is not. HealthRX runs the same clinician-first model as FormBlends: a licensed evaluation upfront, dispensing through a regulated pharmacy instead of a chemicals storefront, and a real point of accountability afterward. A research-chemical vendor ships the vial with no medical review, no prescription, and no licensed party standing behind it.

Does a certificate of analysis from a research-chemical vendor make it safe to buy? A self-commissioned COA beats total silence, but it does not do what most buyers assume. It is paid for by the seller, it cannot screen moles or blood pressure, and it is not the regulated chain of custody a licensed pharmacy maintains. Most importantly, a lab sheet cannot tell a buyer that, given their own skin type and mole history, the smarter call might be not using the compound at all.

What is Melanotan II and how does it actually work?

Melanotan II is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone, the body’s natural signal for producing more melanin. Researchers first developed it at the University of Arizona in the 1980s while searching for a sunburn-protection drug. It binds to melanocortin receptors, triggering pigmentation while also touching appetite, sexual arousal, and other functions. It has never been approved by the FDA or by most other regulatory bodies worldwide.

Does Melanotan 2 work without sun exposure?

It produces some pigmentation without UV exposure, but the effect is noticeably weaker than when paired with sunlight or a tanning bed. The peptide primes melanocytes to produce eumelanin faster and in greater volume, but UV light remains the main trigger for that production. People with very fair skin or low baseline melanin tend to see the weakest results when skipping sun exposure entirely.

How much Melanotan 2 should someone take?

There is no clinically established safe dose, because no regulatory body has approved Melanotan II for human use, which means any number circulating online is anecdotal at best. Research trials used doses in roughly the range of 0.01 mg per kilogram of body weight, but those were controlled settings under medical supervision. Without a prescribing physician tracking the response, self-titrating carries real risk of nausea, facial flushing, and spontaneous erections. A physician-supervised compounding route, like FormBlends, is the only setting where dosing carries any real accountability behind it.

Where can you actually buy Melanotan 2 from a reputable source?

Here is the uncomfortable part: in the US, UK, Australia, and most of Europe, Melanotan II is not approved for sale as a drug or supplement, so no retail source operates fully inside the law. Most vendors selling it as a “research chemical” or “peptide kit” occupy a legal gray zone with no quality oversight whatsoever. The closest thing to a reputable channel is a licensed compounding pharmacy working under a physician’s supervision, which at least offers accountability, purity testing, and a real prescriber in the loop.

References (primary sources, verified)

Every clinical and regulatory claim links to a primary source on PubMed. Each PMID resolves to the exact paper named and supports the exact claim attached to it.

1. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 1996. PMID 8637402. https://pubmed.ncbi.nlm.nih.gov/8637402/
2. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology, 2004. PMID 15262693. https://pubmed.ncbi.nlm.nih.gov/15262693/
3. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 2000. PMID 11035391.
4. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology, 2014. PMID 24355990.
5. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology (Philadelphia), 2012. PMID 23121206.
6. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports, 2019. PMID 30796078.
7. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 2017. PMID 28266027.
8. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ, 2009. PMID 19224885.
9. Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. American Journal of Clinical Dermatology, 2016. PMID 26979527.